08:58 AM EDT, 09/12/2024 (MT Newswires) -- Monopar Therapeutics ( MNPR ) shares rose more than 105% in Thursday's premarket activity after the company said early data from an ongoing phase 1 imaging and dosimetry trial confirmed MNPR-101-Zr's ability to target cancer tumors.

The drug is a monoclonal antibody that targets triple-negative breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers, the company said. MNPR-101-Zr is being evaluated against FDG, the current standard of care.

Monopar said it recently received clearance in Australia to initiate a phase 1 therapeutic clinical trial, set to begin in Q4.

Price: 4.9401, Change: +2.54, Percent Change: +105.84